[1]Patent:US2004/138466,2004,A1.Locationinpatent:Page5
[2]Patent:JP2004/524303,2004,A.Locationinpatent:Page/Pagecolumn12-13
[3]Patent:JP2004/524303,2004,A.Locationinpatent:Page/Pagecolumn13
[4]Patent:US2004/138466,2004,A1.Locationinpatent:Page5
[5]Patent:US2004/138466,2004,A1.Locationinpatent:Page5
[6]Patent:US2004/138466,2004,A1.Locationinpatent:Page4-5
[7]Patent:US2004/138466,2004,A1.Locationinpatent:Page5
[8]Patent:JP2004/524303,2004,A.Locationinpatent:Page/Pagecolumn13
[9]Patent:US2004/138466,2004,A1.Locationinpatent:Page5
[10]Patent:US2004/138466,2004,A1.Locationinpatent:Page5
[11]Patent:US2004/138466,2004,A1.Locationinpatent:Page5
[12]Patent:US2004/138466,2004,A1.Locationinpatent:Page5
[1]Patent:WO2009/66321,2009,A2.Locationinpatent:Page/Pagecolumn19
[2]Patent:WO2009/66321,2009,A2.Locationinpatent:Page/Pagecolumn19-20
[3]Patent:WO2010/43601,2010,A1.Locationinpatent:Page/Pagecolumn31
[4]Patent:WO2010/43601,2010,A1.Locationinpatent:Page/Pagecolumn30;31
[5]SyntheticCommunications,2015,vol.45,p.70-77
[6]Patent:US10307748,2019,B2.Locationinpatent:Page/Pagecolumn12;13
[1]SyntheticCommunications,2015,vol.45,p.70-77
[2]Patent:US10307748,2019,B2.Locationinpatent:Page/Pagecolumn12;13;14;15;17;18
[1]Kern,Fredy;Khatri,Yogan;Litzenburger,Martin;Bernhardt,Rita[DrugMetabolismandDisposition,2016,vol.44,#4,p.495-504]
Title: Omeprazole limited sampling strategies to predict area under the concentration-time curve ratios: implications for cytochrome P450 2C19 and 3A phenotyping.
Journal: European journal of clinical pharmacology 20120401
Title: Induction of CYP2C19 and CYP3A activity following repeated administration of efavirenz in healthy volunteers.
Journal: Clinical pharmacology and therapeutics 20120301
Title: Prediction of relative in vivo metabolite exposure from in vitro data using two model drugs: dextromethorphan and omeprazole.
Journal: Drug metabolism and disposition: the biological fate of chemicals 20120101
Title: Sex and CYP3A5 genotype influence total CYP3A activity: high CYP3A activity and a unique distribution of CYP3A5 variant alleles in Ethiopians.
Journal: The pharmacogenomics journal 20110401
Title: CYP2C19 haplotypes in Koreans as a marker of enzyme activity evaluated with omeprazole.
Journal: Journal of clinical pharmacy and therapeutics 20090801
Title: Effects of the CYP3A5 genotype on omeprazole sulfoxidation in CYP2C19 PMs.
Journal: European journal of clinical pharmacology 20080601
Title: Herbal medicine yin zhi huang induces CYP3A4-mediated sulfoxidation and CYP2C19-dependent hydroxylation of omeprazole.
Journal: Acta pharmacologica Sinica 20071001
Title: Validation of chromatographic methods: evaluation of detection and quantification limits in the determination of impurities in omeprazole.
Journal: Journal of chromatography. A 20070713
Title: Determination of esomeprazole and its two main metabolites in human, rat and dog plasma by liquid chromatography with tandem mass spectrometry.
Journal: Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20070401
Title: A simple and sensitive bioanalytical assay for simultaneous determination of omeprazole and its three major metabolites in human blood plasma using RP-HPLC after a simple liquid-liquid extraction procedure.
Journal: Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20061205
Title: Determination of omeprazole, hydroxyomeprazole and omeprazole sulfone using automated solid phase extraction and micellar electrokinetic capillary chromatography.
Journal: Journal of pharmaceutical and biomedical analysis 20060911
Title: Use of omeprazole sulfone in a single plasma sample as a probe for CYP3A4.
Journal: European journal of clinical pharmacology 20060801
Title: Use of omeprazole as a CYP3A probe drug: effect of sex and menstrual cycle phase on CYP3A activity in healthy Caucasian adults.
Journal: Journal of clinical pharmacology 20060301
Title: Esomeprazole-induced healing of gastroesophageal reflux disease is unrelated to the genotype of CYP2C19: evidence from clinical and pharmacokinetic data.
Journal: Clinical pharmacology and therapeutics 20051201
Title: The effect of aging on the relationship between the cytochrome P450 2C19 genotype and omeprazole pharmacokinetics.
Journal: Clinical pharmacokinetics 20050101
Title: Metabolism of omeprazole after two oral doses in children 1 to 9 months old.
Journal: Proceedings of the Western Pharmacology Society 20050101
Title: Pharmacogenetics and herb-drug interactions: experience with Ginkgo biloba and omeprazole.
Journal: Pharmacogenetics 20041201
Title: Omeprazole treatment of Korean patients: effects on gastric pH and gastrin release in relation to CYP2C19 geno- and phenotypes.
Journal: Basic & clinical pharmacology & toxicology 20040901
Title: Omeprazole as a CYP2C19 marker in Chinese subjects: assessment of its gene-dose effect and intrasubject variability.
Journal: Journal of clinical pharmacology 20040601
Title: Assay of omeprazole and omeprazole sulfone by semi-microcolumn liquid chromatography with mixed-function precolumn.
Journal: Journal of chromatography. B, Biomedical sciences and applications 20010425
Title: Omeprazole and lansoprazole are mixed inducers of CYP1A and CYP3A in human hepatocytes in primary culture.
Journal: The Journal of pharmacology and experimental therapeutics 19940401
